[go: up one dir, main page]

GB201114389D0 - Novel compounds - Google Patents

Novel compounds

Info

Publication number
GB201114389D0
GB201114389D0 GBGB1114389.8A GB201114389A GB201114389D0 GB 201114389 D0 GB201114389 D0 GB 201114389D0 GB 201114389 A GB201114389 A GB 201114389A GB 201114389 D0 GB201114389 D0 GB 201114389D0
Authority
GB
United Kingdom
Prior art keywords
compounds
novel compounds
activity
formula
gpr1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1114389.8A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Prosidion Ltd
Original Assignee
Prosidion Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prosidion Ltd filed Critical Prosidion Ltd
Priority to GBGB1114389.8A priority Critical patent/GB201114389D0/en
Publication of GB201114389D0 publication Critical patent/GB201114389D0/en
Priority to PCT/EP2011/070346 priority patent/WO2012066077A1/en
Priority to ARP110104288A priority patent/AR083904A1/en
Priority to TW100140728A priority patent/TW201249828A/en
Priority to PCT/EP2012/057964 priority patent/WO2013026587A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Therapeutic compounds are disclosed having the general formula (I) that are useful for the treatment of metabolic disorders, including type II diabetes. The compounds have activity as agonists of GPR1 19. Compounds having stereochemistry of formula (la) may also demonstrate DPP-IV inhibitory activity.
GBGB1114389.8A 2010-11-18 2011-08-22 Novel compounds Ceased GB201114389D0 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
GBGB1114389.8A GB201114389D0 (en) 2011-08-22 2011-08-22 Novel compounds
PCT/EP2011/070346 WO2012066077A1 (en) 2010-11-18 2011-11-17 1,4 di substituted pyrrolidine - 3 - yl -amine derivatives and their use for the treatment of metabolic disorders
ARP110104288A AR083904A1 (en) 2010-11-18 2011-11-17 DERIVATIVES OF DISPOSED 1,4-PIRROLIDINS AND 3-IL-AMINAS AND THEIR USES IN THE TREATMENT OF METABOLIC DISORDERS
TW100140728A TW201249828A (en) 2010-11-18 2011-11-18 Novel compounds
PCT/EP2012/057964 WO2013026587A1 (en) 2011-08-22 2012-05-01 1,4 disubstituted pyrrolidine - 3 - yl -amine derivatives and their use for the treatment of metabolic disorders

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1114389.8A GB201114389D0 (en) 2011-08-22 2011-08-22 Novel compounds

Publications (1)

Publication Number Publication Date
GB201114389D0 true GB201114389D0 (en) 2011-10-05

Family

ID=44800623

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1114389.8A Ceased GB201114389D0 (en) 2010-11-18 2011-08-22 Novel compounds

Country Status (2)

Country Link
GB (1) GB201114389D0 (en)
WO (1) WO2013026587A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117777121A (en) * 2016-10-24 2024-03-29 詹森药业有限公司 Compounds and their uses
KR20190108118A (en) 2017-01-06 2019-09-23 유마니티 테라퓨틱스, 인크. Methods for the Treatment of Nervous System Disorders
WO2019084157A1 (en) 2017-10-24 2019-05-02 Yumanity Therapeutics, Inc. Compounds and uses thereof
JP7517992B2 (en) 2018-03-23 2024-07-17 ヤンセン ファーマシューティカ エヌ．ベー． Compounds and their uses
BR112021014583A2 (en) 2019-01-24 2021-10-05 Yumanity Therapeutics, Inc. COMPOUNDS AND USES THEREOF
EA202192047A1 (en) 2019-11-13 2021-12-08 Юманити Терапьютикс, Инк. COMPOUNDS AND THEIR APPLICATIONS
CN111303083A (en) * 2020-03-31 2020-06-19 安徽中羰碳一工业技术有限责任公司 Synthetic method of 3-aminomethyl tetrahydrofuran

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6221660B1 (en) 1999-02-22 2001-04-24 Synaptic Pharmaceutical Corporation DNA encoding SNORF25 receptor
HU227684B1 (en) 2003-08-29 2011-11-28 Sanofi Aventis Adamantane and azabicyclo-octane and nonane derivatives and their use as dpp-iv inhibitors
AU2004303604B2 (en) 2003-12-24 2011-03-24 Prosidion Limited Heterocyclic derivatives as GPCR receptor agonists
EP1838706A1 (en) 2004-12-24 2007-10-03 Prosidion Limited G-protein coupled receptor agonists
KR20070091038A (en) 2004-12-24 2007-09-06 프로시디온 리미티드 Ｇ-protein-coupled receptor (JPP116) agonists and their use to treat obesity and diabetes
GB0428514D0 (en) 2004-12-31 2005-02-09 Prosidion Ltd Compounds
MX2007016508A (en) 2005-06-30 2008-03-04 Prosidion Ltd Gpcr agonists.
US20090325924A1 (en) 2005-06-30 2009-12-31 Stuart Edward GPCR Agonists
BRPI0612599A2 (en) 2005-06-30 2010-11-23 Prosidion Ltd compound, pharmaceutical composition comprising the same, method of treatment and use thereof
US20090221644A1 (en) 2005-06-30 2009-09-03 Stuart Edward Bradley Gpcr Agonists
US20090221639A1 (en) 2006-04-06 2009-09-03 Lisa Sarah Bertram Heterocyclic GPCR Agonists
GB0607196D0 (en) 2006-04-11 2006-05-17 Prosidion Ltd G-protein coupled receptor agonists
WO2007148185A2 (en) 2006-06-21 2007-12-27 Pfizer Products Inc. Substituted 3 -amino- pyrrolidino-4 -lactams as dpp inhibitors
GB0700122D0 (en) 2007-01-04 2007-02-14 Prosidion Ltd GPCR agonists
AR064735A1 (en) 2007-01-04 2009-04-22 Prosidion Ltd GPCR AGONISTS AND PHARMACEUTICAL COMPOSITION BASED ON THE COMPOUND
CL2008000017A1 (en) 2007-01-04 2008-08-01 Prosidion Ltd COMPOUNDS DERIVED FROM NITROGEN AND OXYGEN HETEROCICLES, GPCR AGONISTS; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND; AND USE OF THE COMPOUND FOR THE TREATMENT OF OBESITY, DIABETES, METABOLIC SYNDROME, HYPERLIPIDEMIA, TOLERANCE
JP2010514828A (en) 2007-01-04 2010-05-06 プロシディオン・リミテッド Piperidine GPCR agonist
BRPI0806312A2 (en) 2007-01-04 2011-09-06 Prosidion Ltd cgpr piperidine agonists
EP2200609A1 (en) 2007-09-10 2010-06-30 Prosidion Limited Compounds for the treatment of metabolic disorders
GB0720389D0 (en) 2007-10-18 2008-11-12 Prosidion Ltd G-Protein Coupled Receptor Agonists
GB0720390D0 (en) 2007-10-18 2007-11-28 Prosidion Ltd G-Protein coupled receptor agonists
GB0812031D0 (en) 2008-07-01 2008-08-06 7Tm Pharma As Thiazole derivatives
MX2011000060A (en) 2008-07-10 2011-02-22 Prosidion Ltd Piperidinyl gpcr agonists.
GB0812649D0 (en) 2008-07-10 2008-08-20 Prosidion Ltd Compounds
ATE557024T1 (en) 2008-07-10 2012-05-15 Prosidion Ltd PIPERIDINE COMPOUNDS AS GPCR AGONISTS
GB0812648D0 (en) 2008-07-10 2008-08-20 Prosidion Ltd Compounds
GB0812642D0 (en) 2008-07-10 2008-08-20 Prosidion Ltd Compounds
GB0812641D0 (en) 2008-07-10 2008-08-20 Prosidion Ltd Compounds
GB0904284D0 (en) 2009-03-12 2009-04-22 Prosidion Ltd Compounds for the treatment of metabolic disorders
GB0904287D0 (en) * 2009-03-12 2009-04-22 Prosidion Ltd Compounds for the treatment of metabolic disorders
GB0904285D0 (en) 2009-03-12 2009-04-22 Prosidion Ltd Compounds for the treatment of metabolic disorders
CN102686579A (en) 2009-10-09 2012-09-19 Irm责任有限公司 Compounds and compositions as modulators of GPR119 activity

Also Published As

Publication number Publication date
WO2013026587A1 (en) 2013-02-28

Similar Documents

Publication Publication Date Title
WO2011147951A8 (en) Cycloamino derivatives as gpr119 agonists
PH12015500860A1 (en) 2-phenyl -5- heterocyclyl -tetrahydro-2h- pyran-3-amine compounds for use in the treatment of diabetes and its associated disorders
MX341565B (en) 3-amino-pyridines as gpbar1 agonists.
PH12014502141A1 (en) New indanyloxydihydrobenzofuranylacetic acid derivatives and their use as gpr40 receptor agonists
MY170713A (en) Treatment protocol of diabetes type 2
MX2010002312A (en) Triazolopyridine compounds and their use as ask inhibitors.
EA201201030A1 (en) 5-Alkinylpyrimidines
UA113051C2 (en) HETEROCYCLIC DERIVATIVES AND THEIR APPLICATIONS IN THE TREATMENT OF NEUROLOGICAL DISORDERS
GEP201706695B (en) Substituted 4-phenyl-pyridi-nes for the treatment of nk-1 receptor related diseases
NZ746950A (en) Heterocyclic gpr119 agonist compounds
MX2011009493A (en) Compounds for the treatment of metabolic disorders.
JO2939B1 (en) Tetrahydro-Pyrido-Pyrimidine Derivatives
EA201490272A1 (en) NEW 4-PIPERIDINYL COMPOUNDS FOR USE AS TANKIRASE INHIBITORS
HK1215579A1 (en) Substituted 2,3-dihydrobenzofuranyl compounds and uses thereof
MX349254B (en) Compounds for treatment of metabolic syndrome.
WO2013061004A8 (en) Novel disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds for use in the treatment of chemokine-mediated diseases
MX2013012652A (en) Derivatives of n- [(1h-pyrazol-1-yl) aryl] - 1h - indole or 1h - indazole - 3 - carboxamide, their preparation and their use as p2y12 antagonists.
GEP20156318B (en) Heteroaryl derivatives as alpha7 nachr modulators
MY164354A (en) Asymmetric ureas and medical uses thereof
MX2014004858A (en) Disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds for use in the treatment of chemokine-mediated pathologies.
GB201114389D0 (en) Novel compounds
MA32505B1 (en) 5-alkynyl-PYRIMIDINE
TN2014000112A1 (en) Ep1 receptor ligands
PH12013500644A1 (en) Co-crystals and salts of ccr3-inhibitors
GB201116017D0 (en) Bi-aromatic and tri-aromatic compounds as nadph oxidase inhibitors

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)